Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AdCLD-CoV19-1 in Healthy Volunteers
NCT05047692Phase 1Completed
- Sponsor
- Cellid Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of AdCLD-CoV19-1 OMI in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Cellid Co., Ltd. Primary endpoints: Incidence of solicited adverse events and Incidence of unsolicited adverse events. Started Sep 2021; status: completed.
02
Drugs
AdCLD-CoV19-1 OMI
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05047692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05047692.